Edition:
Deutschland

Abbvie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

87.84USD
13 Dec 2019
Change (% chg)

$-0.89 (-1.00%)
Prev Close
$88.73
Open
$88.58
Day's High
$89.08
Day's Low
$87.33
Volume
1,417,559
Avg. Vol
1,962,074
52-wk High
$92.99
52-wk Low
$62.68

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Buy/Sell

Sell Hold Buy
2.00 Mean rating from 11 analysts

Overall

Beta: 0.95
Market Cap(Mil.): $131,219.91
Shares Outstanding(Mil.): 1,478.87
Dividend: 1.18
Yield (%): 5.32

Belgium's UCB says psoriasis drug beats AbbVie's Humira in trial

Dec 6 UCB SA said on Friday its experimental plaque psoriasis drug produced better results compared to AbbVie Inc's blockbuster drug, Humira, in reducing the severity of the disease.

Photo

Drugmakers slash prices in China to get on reimbursement list

BEIJING/SHANGHAI Drugmakers including Roche and Novartis' have agreed to cut the prices of some of their newest drugs by an average of 61% in China in order to get on a national reimbursement scheme list, regulators said.

Photo

Drugmakers slash prices in China to get on reimbursement list

BEIJING/SHANGHAI Drugmakers including Roche and Novartis' have agreed to cut the prices of some of their newest drugs by an average of 61% in China in order to get on a national reimbursement scheme list, regulators said.

Drugmakers slash prices in China to get on reimbursement list

BEIJING/SHANGHAI, Nov 28 Drugmakers including Roche and Novartis' have agreed to cut the prices of some of their newest drugs by an average of 61% in China in order to get on a national reimbursement scheme list, regulators said.

Photo

AstraZeneca shares rise on early U.S. approval for leukaemia drug

FRANKFURT AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukaemia drug, in a challenge to rival AbbVie .

Photo

AstraZeneca shares rise on early U.S. approval for leukemia drug

FRANKFURT AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukemia drug, in a challenge to rival AbbVie .

AstraZeneca shares rise on early U.S. approval for leukaemia drug

FRANKFURT, Nov 22 AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukaemia drug, in a challenge to rival AbbVie.

UPDATE 2-China's BeiGene gets FDA approval for drug to treat rare form of lymphoma

Nov 14 The U.S. Food and Drug Administration on Thursday approved BeiGene Ltd's lymphoma treatment, validating the China-based drugmaker's strategy of largely using data from trials held outside the United States to file for approval.

Abbott CEO Miles White to step down next year

Abbott Laboratories longtime Chief Executive Officer Miles White will step down in favour of his chief of operations in March, handing over the reins after successfully reshaping the healthcare conglomerate in a series of transformative deals.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.24%
Rohstoffe +0.50%
Industrie +0.54%
Konjunktur abhängige Waren & Dienstleistungen +0.62%
Konjunktur unabhängige Waren & Dienstleistungen +0.21%
Finanzindustrie +0.15%
Pharma +0.50%
Technologie -0.02%
Telekommunikation +1.13%

Nachrichten aus der Wirtschaft